Cargando…

Conventional Cancer Therapies Can Accelerate Malignant Potential of Cancer Cells by Activating Cancer-Associated Fibroblasts in Esophageal Cancer Models

SIMPLE SUMMARY: In esophageal cancer, the 5-year survival rate for patients who underwent esophagectomy with chemoradiotherapy is poor, with an estimated rate of 32.4%. One reason for this outcome is the low response rate to preoperative chemotherapy or radiotherapy. In this study, we revealed that...

Descripción completa

Detalles Bibliográficos
Autores principales: Komoto, Satoshi, Noma, Kazuhiro, Kato, Takuya, Kobayashi, Teruki, Nishiwaki, Noriyuki, Narusaka, Toru, Sato, Hiroaki, Katsura, Yuki, Kashima, Hajime, Kikuchi, Satoru, Ohara, Toshiaki, Tazawa, Hiroshi, Fujiwara, Toshiyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252052/
https://www.ncbi.nlm.nih.gov/pubmed/37296933
http://dx.doi.org/10.3390/cancers15112971
_version_ 1785056078742945792
author Komoto, Satoshi
Noma, Kazuhiro
Kato, Takuya
Kobayashi, Teruki
Nishiwaki, Noriyuki
Narusaka, Toru
Sato, Hiroaki
Katsura, Yuki
Kashima, Hajime
Kikuchi, Satoru
Ohara, Toshiaki
Tazawa, Hiroshi
Fujiwara, Toshiyoshi
author_facet Komoto, Satoshi
Noma, Kazuhiro
Kato, Takuya
Kobayashi, Teruki
Nishiwaki, Noriyuki
Narusaka, Toru
Sato, Hiroaki
Katsura, Yuki
Kashima, Hajime
Kikuchi, Satoru
Ohara, Toshiaki
Tazawa, Hiroshi
Fujiwara, Toshiyoshi
author_sort Komoto, Satoshi
collection PubMed
description SIMPLE SUMMARY: In esophageal cancer, the 5-year survival rate for patients who underwent esophagectomy with chemoradiotherapy is poor, with an estimated rate of 32.4%. One reason for this outcome is the low response rate to preoperative chemotherapy or radiotherapy. In this study, we revealed that low-dose chemotherapy or radiotherapy causes malignant phenotypic changes, such as cancer-associated fibroblasts, in normal fibroblasts. Furthermore, radiotherapy-resistant fibroblasts significantly increased the total number of tumors in the peritoneal cavity compared to the control group in peritoneal-disseminated tumor models. Thus, conventional cancer therapy has anti-therapeutic effects via activation of fibroblasts, and it is important to determine which modality of esophageal cancer treatment is selected or combined, recognizing that inappropriate radiotherapy and chemotherapy can lead to tumor resistance. ABSTRACT: Esophageal cancer is one of the most aggressive tumors, and the outcome remains poor. One contributing factor is the presence of tumors that are less responsive or have increased malignancy when treated with conventional chemotherapy, radiotherapy, or a combination of these. Cancer-associated fibroblasts (CAFs) play an important role in the tumor microenvironment. Focusing on conventional cancer therapies, we investigated how CAFs acquire therapeutic resistance and how they affect tumor malignancy. In this study, low-dose chemotherapy or radiotherapy-induced normal fibroblasts showed enhanced activation of CAFs markers, fibroblast activation protein, and α-smooth muscle actin, indicating the acquisition of malignancy in fibroblasts. Furthermore, CAFs activated by radiotherapy induce phenotypic changes in cancer cells, increasing their proliferation, migration, and invasion abilities. In in vivo peritoneal dissemination models, the total number of tumor nodules in the abdominal cavity was significantly increased in the co-inoculation group of cancer cells and resistant fibroblasts compared to that in the co-inoculation group of cancer cells and normal fibroblasts. In conclusion, we demonstrated that conventional cancer therapy causes anti-therapeutic effects via the activation of fibroblasts, resulting in CAFs. It is important to select or combine modalities of esophageal cancer treatment, recognizing that inappropriate radiotherapy and chemotherapy can lead to resistance in CAF-rich tumors.
format Online
Article
Text
id pubmed-10252052
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102520522023-06-10 Conventional Cancer Therapies Can Accelerate Malignant Potential of Cancer Cells by Activating Cancer-Associated Fibroblasts in Esophageal Cancer Models Komoto, Satoshi Noma, Kazuhiro Kato, Takuya Kobayashi, Teruki Nishiwaki, Noriyuki Narusaka, Toru Sato, Hiroaki Katsura, Yuki Kashima, Hajime Kikuchi, Satoru Ohara, Toshiaki Tazawa, Hiroshi Fujiwara, Toshiyoshi Cancers (Basel) Article SIMPLE SUMMARY: In esophageal cancer, the 5-year survival rate for patients who underwent esophagectomy with chemoradiotherapy is poor, with an estimated rate of 32.4%. One reason for this outcome is the low response rate to preoperative chemotherapy or radiotherapy. In this study, we revealed that low-dose chemotherapy or radiotherapy causes malignant phenotypic changes, such as cancer-associated fibroblasts, in normal fibroblasts. Furthermore, radiotherapy-resistant fibroblasts significantly increased the total number of tumors in the peritoneal cavity compared to the control group in peritoneal-disseminated tumor models. Thus, conventional cancer therapy has anti-therapeutic effects via activation of fibroblasts, and it is important to determine which modality of esophageal cancer treatment is selected or combined, recognizing that inappropriate radiotherapy and chemotherapy can lead to tumor resistance. ABSTRACT: Esophageal cancer is one of the most aggressive tumors, and the outcome remains poor. One contributing factor is the presence of tumors that are less responsive or have increased malignancy when treated with conventional chemotherapy, radiotherapy, or a combination of these. Cancer-associated fibroblasts (CAFs) play an important role in the tumor microenvironment. Focusing on conventional cancer therapies, we investigated how CAFs acquire therapeutic resistance and how they affect tumor malignancy. In this study, low-dose chemotherapy or radiotherapy-induced normal fibroblasts showed enhanced activation of CAFs markers, fibroblast activation protein, and α-smooth muscle actin, indicating the acquisition of malignancy in fibroblasts. Furthermore, CAFs activated by radiotherapy induce phenotypic changes in cancer cells, increasing their proliferation, migration, and invasion abilities. In in vivo peritoneal dissemination models, the total number of tumor nodules in the abdominal cavity was significantly increased in the co-inoculation group of cancer cells and resistant fibroblasts compared to that in the co-inoculation group of cancer cells and normal fibroblasts. In conclusion, we demonstrated that conventional cancer therapy causes anti-therapeutic effects via the activation of fibroblasts, resulting in CAFs. It is important to select or combine modalities of esophageal cancer treatment, recognizing that inappropriate radiotherapy and chemotherapy can lead to resistance in CAF-rich tumors. MDPI 2023-05-30 /pmc/articles/PMC10252052/ /pubmed/37296933 http://dx.doi.org/10.3390/cancers15112971 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Komoto, Satoshi
Noma, Kazuhiro
Kato, Takuya
Kobayashi, Teruki
Nishiwaki, Noriyuki
Narusaka, Toru
Sato, Hiroaki
Katsura, Yuki
Kashima, Hajime
Kikuchi, Satoru
Ohara, Toshiaki
Tazawa, Hiroshi
Fujiwara, Toshiyoshi
Conventional Cancer Therapies Can Accelerate Malignant Potential of Cancer Cells by Activating Cancer-Associated Fibroblasts in Esophageal Cancer Models
title Conventional Cancer Therapies Can Accelerate Malignant Potential of Cancer Cells by Activating Cancer-Associated Fibroblasts in Esophageal Cancer Models
title_full Conventional Cancer Therapies Can Accelerate Malignant Potential of Cancer Cells by Activating Cancer-Associated Fibroblasts in Esophageal Cancer Models
title_fullStr Conventional Cancer Therapies Can Accelerate Malignant Potential of Cancer Cells by Activating Cancer-Associated Fibroblasts in Esophageal Cancer Models
title_full_unstemmed Conventional Cancer Therapies Can Accelerate Malignant Potential of Cancer Cells by Activating Cancer-Associated Fibroblasts in Esophageal Cancer Models
title_short Conventional Cancer Therapies Can Accelerate Malignant Potential of Cancer Cells by Activating Cancer-Associated Fibroblasts in Esophageal Cancer Models
title_sort conventional cancer therapies can accelerate malignant potential of cancer cells by activating cancer-associated fibroblasts in esophageal cancer models
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10252052/
https://www.ncbi.nlm.nih.gov/pubmed/37296933
http://dx.doi.org/10.3390/cancers15112971
work_keys_str_mv AT komotosatoshi conventionalcancertherapiescanacceleratemalignantpotentialofcancercellsbyactivatingcancerassociatedfibroblastsinesophagealcancermodels
AT nomakazuhiro conventionalcancertherapiescanacceleratemalignantpotentialofcancercellsbyactivatingcancerassociatedfibroblastsinesophagealcancermodels
AT katotakuya conventionalcancertherapiescanacceleratemalignantpotentialofcancercellsbyactivatingcancerassociatedfibroblastsinesophagealcancermodels
AT kobayashiteruki conventionalcancertherapiescanacceleratemalignantpotentialofcancercellsbyactivatingcancerassociatedfibroblastsinesophagealcancermodels
AT nishiwakinoriyuki conventionalcancertherapiescanacceleratemalignantpotentialofcancercellsbyactivatingcancerassociatedfibroblastsinesophagealcancermodels
AT narusakatoru conventionalcancertherapiescanacceleratemalignantpotentialofcancercellsbyactivatingcancerassociatedfibroblastsinesophagealcancermodels
AT satohiroaki conventionalcancertherapiescanacceleratemalignantpotentialofcancercellsbyactivatingcancerassociatedfibroblastsinesophagealcancermodels
AT katsurayuki conventionalcancertherapiescanacceleratemalignantpotentialofcancercellsbyactivatingcancerassociatedfibroblastsinesophagealcancermodels
AT kashimahajime conventionalcancertherapiescanacceleratemalignantpotentialofcancercellsbyactivatingcancerassociatedfibroblastsinesophagealcancermodels
AT kikuchisatoru conventionalcancertherapiescanacceleratemalignantpotentialofcancercellsbyactivatingcancerassociatedfibroblastsinesophagealcancermodels
AT oharatoshiaki conventionalcancertherapiescanacceleratemalignantpotentialofcancercellsbyactivatingcancerassociatedfibroblastsinesophagealcancermodels
AT tazawahiroshi conventionalcancertherapiescanacceleratemalignantpotentialofcancercellsbyactivatingcancerassociatedfibroblastsinesophagealcancermodels
AT fujiwaratoshiyoshi conventionalcancertherapiescanacceleratemalignantpotentialofcancercellsbyactivatingcancerassociatedfibroblastsinesophagealcancermodels